Cargando…

Correlation of liver enhancement in gadoxetic acid–enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial

OBJECTIVES: To evaluate the correlation between liver enhancement on hepatobiliary phase and liver function parameters in a multicenter, multivendor study. METHODS: A total of 359 patients who underwent gadoxetic acid–enhanced MRI using a standardized protocol with various scanners within a prospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Öcal, Osman, Peynircioglu, Bora, Loewe, Christian, van Delden, Otto, Vandecaveye, Vincent, Gebauer, Bernhard, Zech, Christoph J., Sengel, Christian, Bargellini, Irene, Iezzi, Roberto, Benito, Alberto, Schütte, Kerstin, Gasbarrini, Antonio, Seidensticker, Ricarda, Wildgruber, Moritz, Pech, Maciej, Malfertheiner, Peter, Ricke, Jens, Seidensticker, Max
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795026/
https://www.ncbi.nlm.nih.gov/pubmed/34467453
http://dx.doi.org/10.1007/s00330-021-08218-9
_version_ 1784640956454141952
author Öcal, Osman
Peynircioglu, Bora
Loewe, Christian
van Delden, Otto
Vandecaveye, Vincent
Gebauer, Bernhard
Zech, Christoph J.
Sengel, Christian
Bargellini, Irene
Iezzi, Roberto
Benito, Alberto
Schütte, Kerstin
Gasbarrini, Antonio
Seidensticker, Ricarda
Wildgruber, Moritz
Pech, Maciej
Malfertheiner, Peter
Ricke, Jens
Seidensticker, Max
author_facet Öcal, Osman
Peynircioglu, Bora
Loewe, Christian
van Delden, Otto
Vandecaveye, Vincent
Gebauer, Bernhard
Zech, Christoph J.
Sengel, Christian
Bargellini, Irene
Iezzi, Roberto
Benito, Alberto
Schütte, Kerstin
Gasbarrini, Antonio
Seidensticker, Ricarda
Wildgruber, Moritz
Pech, Maciej
Malfertheiner, Peter
Ricke, Jens
Seidensticker, Max
author_sort Öcal, Osman
collection PubMed
description OBJECTIVES: To evaluate the correlation between liver enhancement on hepatobiliary phase and liver function parameters in a multicenter, multivendor study. METHODS: A total of 359 patients who underwent gadoxetic acid–enhanced MRI using a standardized protocol with various scanners within a prospective multicenter phase II trial (SORAMIC) were evaluated. The correlation between liver enhancement on hepatobiliary phase normalized to the spleen (liver-to-spleen ratio, LSR) and biochemical laboratory parameters, clinical findings related to liver functions, liver function grading systems (Child-Pugh and Albumin-Bilirubin [ALBI]), and scanner characteristics were analyzed using uni- and multivariate analyses. RESULTS: There was a significant positive correlation between LSR and albumin (rho = 0.193; p < 0.001), platelet counts (rho = 0.148; p = 0.004), and sodium (rho = 0.161; p = 0.002); and a negative correlation between LSR and total bilirubin (rho = −0.215; p < 0.001) and AST (rho = −0.191; p < 0.001). Multivariate analysis confirmed independent significance for each of albumin (p = 0.022), total bilirubin (p = 0.045), AST (p = 0.031), platelet counts (p = 0.012), and sodium (p = 0.006). The presence of ascites (1.47 vs. 1.69, p < 0.001) and varices (1.55 vs. 1.69, p = 0.006) was related to significantly lower LSR. Similarly, patients with ALBI grade 1 had significantly higher LSR than patients with grade 2 (1.74 ± 0.447 vs. 1.56 ± 0.408, p < 0.001); and Child-Pugh A patients had a significantly higher LSR than Child-Pugh B (1.67 ± 0.44 vs. 1.49 ± 0.33, p = 0.021). Also, LSR was negatively correlated with MELD-Na scores (rho = −0.137; p = 0.013). However, one scanner brand was significantly associated with lower LSR (p < 0.001). CONCLUSIONS: The liver enhancement on the hepatobiliary phase of gadoxetic acid–enhanced MRI is correlated with biomarkers of liver functions in a multicenter cohort. However, this correlation shows variations between scanner brands. KEY POINTS: • The correlation between liver enhancement on the hepatobiliary phase of gadoxetic acid–enhanced MRI and liver function is consistent in a multicenter-multivendor cohort. • Signal intensity–based indices (liver-to-spleen ratio) can be used as an imaging biomarker of liver function. • However, absolute values might change between vendors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00330-021-08218-9.
format Online
Article
Text
id pubmed-8795026
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-87950262022-02-02 Correlation of liver enhancement in gadoxetic acid–enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial Öcal, Osman Peynircioglu, Bora Loewe, Christian van Delden, Otto Vandecaveye, Vincent Gebauer, Bernhard Zech, Christoph J. Sengel, Christian Bargellini, Irene Iezzi, Roberto Benito, Alberto Schütte, Kerstin Gasbarrini, Antonio Seidensticker, Ricarda Wildgruber, Moritz Pech, Maciej Malfertheiner, Peter Ricke, Jens Seidensticker, Max Eur Radiol Magnetic Resonance OBJECTIVES: To evaluate the correlation between liver enhancement on hepatobiliary phase and liver function parameters in a multicenter, multivendor study. METHODS: A total of 359 patients who underwent gadoxetic acid–enhanced MRI using a standardized protocol with various scanners within a prospective multicenter phase II trial (SORAMIC) were evaluated. The correlation between liver enhancement on hepatobiliary phase normalized to the spleen (liver-to-spleen ratio, LSR) and biochemical laboratory parameters, clinical findings related to liver functions, liver function grading systems (Child-Pugh and Albumin-Bilirubin [ALBI]), and scanner characteristics were analyzed using uni- and multivariate analyses. RESULTS: There was a significant positive correlation between LSR and albumin (rho = 0.193; p < 0.001), platelet counts (rho = 0.148; p = 0.004), and sodium (rho = 0.161; p = 0.002); and a negative correlation between LSR and total bilirubin (rho = −0.215; p < 0.001) and AST (rho = −0.191; p < 0.001). Multivariate analysis confirmed independent significance for each of albumin (p = 0.022), total bilirubin (p = 0.045), AST (p = 0.031), platelet counts (p = 0.012), and sodium (p = 0.006). The presence of ascites (1.47 vs. 1.69, p < 0.001) and varices (1.55 vs. 1.69, p = 0.006) was related to significantly lower LSR. Similarly, patients with ALBI grade 1 had significantly higher LSR than patients with grade 2 (1.74 ± 0.447 vs. 1.56 ± 0.408, p < 0.001); and Child-Pugh A patients had a significantly higher LSR than Child-Pugh B (1.67 ± 0.44 vs. 1.49 ± 0.33, p = 0.021). Also, LSR was negatively correlated with MELD-Na scores (rho = −0.137; p = 0.013). However, one scanner brand was significantly associated with lower LSR (p < 0.001). CONCLUSIONS: The liver enhancement on the hepatobiliary phase of gadoxetic acid–enhanced MRI is correlated with biomarkers of liver functions in a multicenter cohort. However, this correlation shows variations between scanner brands. KEY POINTS: • The correlation between liver enhancement on the hepatobiliary phase of gadoxetic acid–enhanced MRI and liver function is consistent in a multicenter-multivendor cohort. • Signal intensity–based indices (liver-to-spleen ratio) can be used as an imaging biomarker of liver function. • However, absolute values might change between vendors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00330-021-08218-9. Springer Berlin Heidelberg 2021-08-31 2022 /pmc/articles/PMC8795026/ /pubmed/34467453 http://dx.doi.org/10.1007/s00330-021-08218-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Magnetic Resonance
Öcal, Osman
Peynircioglu, Bora
Loewe, Christian
van Delden, Otto
Vandecaveye, Vincent
Gebauer, Bernhard
Zech, Christoph J.
Sengel, Christian
Bargellini, Irene
Iezzi, Roberto
Benito, Alberto
Schütte, Kerstin
Gasbarrini, Antonio
Seidensticker, Ricarda
Wildgruber, Moritz
Pech, Maciej
Malfertheiner, Peter
Ricke, Jens
Seidensticker, Max
Correlation of liver enhancement in gadoxetic acid–enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial
title Correlation of liver enhancement in gadoxetic acid–enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial
title_full Correlation of liver enhancement in gadoxetic acid–enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial
title_fullStr Correlation of liver enhancement in gadoxetic acid–enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial
title_full_unstemmed Correlation of liver enhancement in gadoxetic acid–enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial
title_short Correlation of liver enhancement in gadoxetic acid–enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial
title_sort correlation of liver enhancement in gadoxetic acid–enhanced mri with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from soramic trial
topic Magnetic Resonance
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795026/
https://www.ncbi.nlm.nih.gov/pubmed/34467453
http://dx.doi.org/10.1007/s00330-021-08218-9
work_keys_str_mv AT ocalosman correlationofliverenhancementingadoxeticacidenhancedmriwithliverfunctionsamulticentermultivendoranalysisofhepatocellularcarcinomapatientsfromsoramictrial
AT peynircioglubora correlationofliverenhancementingadoxeticacidenhancedmriwithliverfunctionsamulticentermultivendoranalysisofhepatocellularcarcinomapatientsfromsoramictrial
AT loewechristian correlationofliverenhancementingadoxeticacidenhancedmriwithliverfunctionsamulticentermultivendoranalysisofhepatocellularcarcinomapatientsfromsoramictrial
AT vandeldenotto correlationofliverenhancementingadoxeticacidenhancedmriwithliverfunctionsamulticentermultivendoranalysisofhepatocellularcarcinomapatientsfromsoramictrial
AT vandecaveyevincent correlationofliverenhancementingadoxeticacidenhancedmriwithliverfunctionsamulticentermultivendoranalysisofhepatocellularcarcinomapatientsfromsoramictrial
AT gebauerbernhard correlationofliverenhancementingadoxeticacidenhancedmriwithliverfunctionsamulticentermultivendoranalysisofhepatocellularcarcinomapatientsfromsoramictrial
AT zechchristophj correlationofliverenhancementingadoxeticacidenhancedmriwithliverfunctionsamulticentermultivendoranalysisofhepatocellularcarcinomapatientsfromsoramictrial
AT sengelchristian correlationofliverenhancementingadoxeticacidenhancedmriwithliverfunctionsamulticentermultivendoranalysisofhepatocellularcarcinomapatientsfromsoramictrial
AT bargelliniirene correlationofliverenhancementingadoxeticacidenhancedmriwithliverfunctionsamulticentermultivendoranalysisofhepatocellularcarcinomapatientsfromsoramictrial
AT iezziroberto correlationofliverenhancementingadoxeticacidenhancedmriwithliverfunctionsamulticentermultivendoranalysisofhepatocellularcarcinomapatientsfromsoramictrial
AT benitoalberto correlationofliverenhancementingadoxeticacidenhancedmriwithliverfunctionsamulticentermultivendoranalysisofhepatocellularcarcinomapatientsfromsoramictrial
AT schuttekerstin correlationofliverenhancementingadoxeticacidenhancedmriwithliverfunctionsamulticentermultivendoranalysisofhepatocellularcarcinomapatientsfromsoramictrial
AT gasbarriniantonio correlationofliverenhancementingadoxeticacidenhancedmriwithliverfunctionsamulticentermultivendoranalysisofhepatocellularcarcinomapatientsfromsoramictrial
AT seidenstickerricarda correlationofliverenhancementingadoxeticacidenhancedmriwithliverfunctionsamulticentermultivendoranalysisofhepatocellularcarcinomapatientsfromsoramictrial
AT wildgrubermoritz correlationofliverenhancementingadoxeticacidenhancedmriwithliverfunctionsamulticentermultivendoranalysisofhepatocellularcarcinomapatientsfromsoramictrial
AT pechmaciej correlationofliverenhancementingadoxeticacidenhancedmriwithliverfunctionsamulticentermultivendoranalysisofhepatocellularcarcinomapatientsfromsoramictrial
AT malfertheinerpeter correlationofliverenhancementingadoxeticacidenhancedmriwithliverfunctionsamulticentermultivendoranalysisofhepatocellularcarcinomapatientsfromsoramictrial
AT rickejens correlationofliverenhancementingadoxeticacidenhancedmriwithliverfunctionsamulticentermultivendoranalysisofhepatocellularcarcinomapatientsfromsoramictrial
AT seidenstickermax correlationofliverenhancementingadoxeticacidenhancedmriwithliverfunctionsamulticentermultivendoranalysisofhepatocellularcarcinomapatientsfromsoramictrial